|
17 Mar 2007 |
Exelixis Files IND Application for XL147
|
|
17 Mar 2007 |
Diffusion Pharmaceuticals Initiates Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC)
|
|
17 Mar 2007 |
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
|
|
17 Mar 2007 |
Nippon Shinyaku and Teva terminate HMN-214 License Agreement
|
|
16 Mar 2007 |
Trimeris and Roche Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors
|
|
16 Mar 2007 |
Acura Pharmaceuticals, Inc. Updates OxyADF Tablets Development Program and Results of Study AP-ADF-102
|
|
16 Mar 2007 |
Eli Lilly Withdraws Its Marketing Authorization Application for Arxxant
|
|
15 Mar 2007 |
Avigen Receives Approval to Initiate AV650 Phase II Clinical Development
|
|
15 Mar 2007 |
Optimer Pharmaceuticals Advances Difimicin into Phase 3 Clinical Trial
|
|
15 Mar 2007 |
Curis Selects First Development Candidate from its Targeted Cancer Drug Development Platform
|
|
15 Mar 2007 |
Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study
|
|
14 Mar 2007 |
Tyrima(TM) Demonstrates Good Safety Profile and Excellent Pharmacokinetic Properties
|
|
14 Mar 2007 |
FDA approves Tykerb(R) (lapatinib) in combination with Xeloda(R) (capecitabine) for the treatment of advanced or metastatic breast cancer in women who have progressed on prior therapy
|
|
14 Mar 2007 |
Spectrum Pharmaceuticals Reaches Special Protocol Assessment Agreement With FDA on Phase 3 Trials for EOquin(R)
|
|
14 Mar 2007 |
Active Biotech's I-3D micro-dosing clinical trial concluded
|
|
14 Mar 2007 |
Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG-irinotecan) for Potential to Treat Patients with Refractory Solid Tumors
|
|
14 Mar 2007 |
Cellzome Receives First Milestone Payment for Alzheimer's Program From Ortho-McNeil Pharmaceutical, Inc
|
|
14 Mar 2007 |
Array BioPharma and VentiRx Pharmaceuticals Announce License Agreement
|
|
14 Mar 2007 |
Xytis Enrolls First Patient in Phase II Clinical Study With Anatibant (XY2405) for Traumatic Brain Injury
|
|
14 Mar 2007 |
Obecure Initiates Phase II Weight Gain Prevention Study for Patients Taking Zyprexa
|
|
14 Mar 2007 |
Memory Pharmaceuticals Commences Phase 2a Trial of MEM 3454 in Alzheimer's Disease
|
|
13 Mar 2007 |
TorreyPines Therapeutics Initiates Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
|
|
13 Mar 2007 |
Panacos Announces Bevirimat Phase 2b Dose Escalation Strategy
|
|
13 Mar 2007 |
Depomed Files Investigational New Drug Application For Gabapentin Gr For The Treatment Of Postmenopausal Hot Flashes
|
|
13 Mar 2007 |
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
|
